Javascript must be enabled to continue!
y-Butyrolactone
View through CrossRef
Abstract
y-Butyrolactone is an oily liquid used as a polymer solvent in products such as paint and nail polish removers. Liquids and powders containing y-butyrolactone were marketed as dietary supplements under product names such as Renew trient, Revivarant, Blue Nitro, Gamma G; these generally claimed improved physical performance, muscle building, reduced stress, and enhanced sexual activity and sleep. In January 1999, after these products had been associated with at least 55 adverse health events and one death, the U.S. Food and Drug Administration urged a voluntary re call of all dietary supplements containing y-butyrolactone. The oral LD5a in rats is 17.2 ml/kg. Rats display absence like seizures after systemic administration of y-butyrolactone or microinfusion of its metabolite, y-hydroxybutyric acid (GHB), into the ventrobasal nucleus of the thalamus. y-Butyrolactone may possess limited y-aminobutyric acid agonist (GABA) activity. GHB is used as a relatively specific inhibitor of central dopamine release ( 3 ). It is suggested that GHB modulates the basal and K+-evoked release of GABA and glutamate in the thalamic ventrobasal relay nuclei (1). GHB-induced absence seizures may regulate GABAA receptor a-1 and a-4 gene expression in thalamic relay nu clei as a compensatory mechanism by which absence sei zures are terminated (2).
Title: y-Butyrolactone
Description:
Abstract
y-Butyrolactone is an oily liquid used as a polymer solvent in products such as paint and nail polish removers.
Liquids and powders containing y-butyrolactone were marketed as dietary supplements under product names such as Renew trient, Revivarant, Blue Nitro, Gamma G; these generally claimed improved physical performance, muscle building, reduced stress, and enhanced sexual activity and sleep.
In January 1999, after these products had been associated with at least 55 adverse health events and one death, the U.
S.
Food and Drug Administration urged a voluntary re call of all dietary supplements containing y-butyrolactone.
The oral LD5a in rats is 17.
2 ml/kg.
Rats display absence like seizures after systemic administration of y-butyrolactone or microinfusion of its metabolite, y-hydroxybutyric acid (GHB), into the ventrobasal nucleus of the thalamus.
y-Butyrolactone may possess limited y-aminobutyric acid agonist (GABA) activity.
GHB is used as a relatively specific inhibitor of central dopamine release ( 3 ).
It is suggested that GHB modulates the basal and K+-evoked release of GABA and glutamate in the thalamic ventrobasal relay nuclei (1).
GHB-induced absence seizures may regulate GABAA receptor a-1 and a-4 gene expression in thalamic relay nu clei as a compensatory mechanism by which absence sei zures are terminated (2).
Related Results
Antimicrobial agents from endophytic fungi Aspergillus terreus isolated from Zingiber cassumunar Roxb. rhizomes
Antimicrobial agents from endophytic fungi Aspergillus terreus isolated from Zingiber cassumunar Roxb. rhizomes
The purpose of this research was to isolate antimicrobial compounds from endophytic fungi isolated from Zingiber cassumunar rhizomes obtained from Surin, Supanburee, Songkhla and P...
Antibiofilm activity of lichen secondary metabolites
Antibiofilm activity of lichen secondary metabolites
Activité anti-biofilm des métabolites secondaires de lichen
Les bactéries buccales n'infectent pas seulement la bouche mais y resident. Elles peuvent également pass...
Closed-loop chemical recycling of a biobased poly(oxanorbornene-fused γ-butyrolactone)
Closed-loop chemical recycling of a biobased poly(oxanorbornene-fused γ-butyrolactone)
New polymers, properly designed for end-of-life and efficiently formed from renewable carbon, are key to the transition to a more sustainable, circular plastics economy. Ring-openi...
50 INVESTIGATION OF THE EFFECT OF BUTYROLACTONE I AND CYCLOHEXIMIDE TREATMENT DURING IN VITRO MATURATION OF SWINE OOCYTES
50 INVESTIGATION OF THE EFFECT OF BUTYROLACTONE I AND CYCLOHEXIMIDE TREATMENT DURING IN VITRO MATURATION OF SWINE OOCYTES
Butyrolactone I and cycloheximide specifically inhibit MPF activation and prevent the resumption of meiosis. The aim of this study was to investigate the kinetics of in vitro matur...
Formation of Tetrahydrofurano-, Aryltetralin, and Butyrolactone Norlignans through the Epoxidation of 9-Norlignans
Formation of Tetrahydrofurano-, Aryltetralin, and Butyrolactone Norlignans through the Epoxidation of 9-Norlignans
Epoxidation of the C=C double bond in unsaturated norlignans derived from hydroxymatairesinol was studied. The intermediate epoxides were formed in up to quantitative conversions a...
Syntheses De γ, γ‐Dimethyl α‐Methylene‐γ‐ Butyrolactone Et d'oxa‐1 Spiro [4,5] Methylene‐3 Decanone‐2 Marquees Au Carbone‐14
Syntheses De γ, γ‐Dimethyl α‐Methylene‐γ‐ Butyrolactone Et d'oxa‐1 Spiro [4,5] Methylene‐3 Decanone‐2 Marquees Au Carbone‐14
Abstract14C‐labelled γ, γ‐dimethyl‐α‐methylene‐γ‐butyrolactone 1 and 1‐oxa‐Spiro [4.5]‐3‐methylene‐2‐decanone 2 have been synthesized from acetone and cyclohexanone respectively an...
Ionic (Co)Organocatalyst with (Thio)Urea Anion and Tetra‑n‑butyl Ammonium Cation for the Polymerization of γ‐Butyrolactone
Ionic (Co)Organocatalyst with (Thio)Urea Anion and Tetra‑n‑butyl Ammonium Cation for the Polymerization of γ‐Butyrolactone
AbstractAn effective ionic organocatalyst system is developed for the challenging ring‐opening polymerization (ROP) of γ‐butyrolactone (GBL) at low temperature. The catalysts are p...
The use of chlordiazepoxide for outpatient gamma-butyrolactone (GBL) detoxification: An observational study
The use of chlordiazepoxide for outpatient gamma-butyrolactone (GBL) detoxification: An observational study
Background
Various detoxification regimens are used for gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL), including diazepam, barbiturates, baclofen an...

